Merck Announces Second-Quarter 2015 Financial Results
Dateline City:
KENILWORTH, N.J.
Second-Quarter 2015 Non-GAAP EPS of $0.86, Excluding Certain Items; GAAP EPS of $0.24
Company Narrows and Raises 2015 Full-Year Non-GAAP EPS Target to $3.45 to $3.55, Excluding Certain Items; Lowers 2015 Full-Year GAAP EPS Target to $1.52 to $1.71
Second-Quarter 2015 Worldwide Sales Were $9.8 Billion, a Decrease of 11 Percent, Including a 7 Percent Net Unfavorable Impact from Acquisitions and Divestitures and a 7 Percent Negative Impact from Foreign Exchange
Second-Quarter Results Reflect Sales Growth in Hospital Acute Care, Oncology and Diabetes and Sales Declines in Cardiovascular and Hepatitis C
European Commission Approved KEYTRUDA for the Treatment of Advanced Melanoma; FDA Accepted sBLA for KEYTRUDA in Advanced Non-Small Cell Lung Cancer
Grazoprevir/Elbasvir Chronic Hepatitis C Combination Regimen Accepted for Regulatory Review in Both the United States and European Union
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced financial results for the second quarter of 2015.
Language:
English
...
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Diabetes | Endocrinology | Heart | Hepatitis | Hepatitis C | Hospitals | Lung Cancer | Melanoma | Merck | Mergers and Aquisitions | Non-Small Cell Lung Cancer | Pharmaceuticals | Skin Cancer